FDA Selects Box's Cloud Content Management Platform

Equities Research  |

The FDA has selected Box's (NYSE: BOX) cloud content management platform to modernize its technical infrastructure and drive new ways to work in the cloud. "The FDA is leading the way on how government agencies are leveraging modern technology to better engage with stakeholders and improve mission outcomes," said Sonny Hashmi, Managing Director of Global Public Sector at Box. "FDA’s investment in a cloud strategy, including partnerships with companies such as Box, is poised to help the agency re-imagine stakeholder engagement, build digital experiences, and bring agility to mission delivery, while ensuring the privacy and security of sensitive data."

Source: Box, Inc.

The US Food and Drug Administration selected Box to:

  • Improve collaboration with third party organizations, including external experts, and supporting audits, discoveries and reviews
  • Digitize and automate processes leveraging Box as a central content portal whereby staff can easily collaborate and share materials internally and with external parties
  • Reduce complexity of infrastructure by eliminating fragmented content and document management tools
  • Provide added cybersecurity control and administrative capabilities necessary to govern and protect sensitive information at scale.

Agencies and departments servicing healthcare, military, educational, judicial, legislative and regulatory components of the US government are using Box to be more efficient, streamlined and agile. Box is FedRAMP (Federal Risk and Authorization Management Program) compliant and recently received Department of Defense Securities Requirements Guide Impact Level 4 Authorization by the Defense Information Systems Agency. With today’s announcement, the FDA joins leading global organizations that have moved to Box to power new ways of working, including the Department of Justice, the District of Columbia Government, General Electric, Procter & Gamble and AstraZeneca.

Please email us at content@equities.com to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Symbol Name Price Change % Volume
BOX Box Inc. Class A 24.16 0.16 0.67 896,208 Trade


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.